Yan Wei, Wu Qin, Shi Yumeng, You Hanxiao, Jia Jieting, Meng Defang, Ma Li, Zhang Xuexiang, Yu Xindi, Tan Wenfeng, Wei Hua
Division of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Division of Rheumatology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Clin Rheumatol. 2025 Jan;44(1):341-348. doi: 10.1007/s10067-024-07265-z. Epub 2024 Dec 16.
Anti-MDA5-positive dermatomyositis (anti-MDA5-DM) is a rare autoimmune disease that often leads to rapid-progressive interstitial lung disease (RP-ILD). The lack of effective prediction and treatment methods makes RP-ILD a major risk factor for death in patients with this condition. S100A6 is a member of the S100 Ca2 + - binding protein family, which plays important roles in inflammation, tumor, injury, and fibroblast reparation. This study aims to explore the correlation between serum S100A6 and RP-ILD in anti-MDA5-DM, and to determine whether S100A6 can be used as a specific biomarker to predict RP-ILD.
The authors enrolled 80 participants, including 20 healthy volunteers, 20 patients with anti-synthase syndrome, and 40 patients with anti-MDA5-positive dermatomyositis. Serum samples were collected and the levels of S100A6 were measured using ELISA. Logistic regression was used to analyze the relationship between serum S100A6 levels and RP-ILD, along with other clinical and laboratory parameters. RESULTS: Serum S100A6 levels were significantly lower in anti-MDA5-DM patients with RP-ILD than those without RP-ILD (odds ratio:0.393 (95% CI, 0.164-0.943, p = 0.036)). High serum S100A6 level was found to be a protective factor for RP-ILD. This study shows that high serum S100A6 level may be a protective factor for RP-ILD in anti-MDA5-DM patients. Serum S100A6 may be used as a specific biomarker to predict whether RP-ILD occurs in anti-MDA5-DM. Key Points • This research discovers and reports a biomarker (S100A6) for distinguishing potential RP-ILD in Anti-MDA5 positive dermatomyositis.
抗黑色素瘤分化相关基因5阳性皮肌炎（anti-MDA5-DM）是一种罕见的自身免疫性疾病，常导致快速进展性间质性肺病（RP-ILD）。缺乏有效的预测和治疗方法使RP-ILD成为该疾病患者死亡的主要危险因素。S100A6是S100 Ca2 +结合蛋白家族的成员，在炎症、肿瘤、损伤和成纤维细胞修复中起重要作用。本研究旨在探讨血清S100A6与anti-MDA5-DM中RP-ILD的相关性，并确定S100A6是否可作为预测RP-ILD的特异性生物标志物。
作者招募了80名参与者，包括20名健康志愿者、20名抗合成酶综合征患者和40名抗MDA5阳性皮肌炎患者。收集血清样本并使用酶联免疫吸附测定法测量S100A6水平。采用逻辑回归分析血清S100A6水平与RP-ILD以及其他临床和实验室参数之间的关系。
患有RP-ILD的anti-MDA5-DM患者的血清S100A6水平显著低于未患RP-ILD的患者（比值比：0.393（95%可信区间，0.164 - 0.943，p = 0.036））。高血清S100A6水平被发现是RP-ILD的保护因素。本研究表明，高血清S100A6水平可能是anti-MDA5-DM患者中RP-ILD的保护因素。血清S100A6可作为预测anti-MDA5-DM患者是否发生RP-ILD的特异性生物标志物。
关键点 • 本研究发现并报告了一种用于区分抗MDA5阳性皮肌炎中潜在RP-ILD的生物标志物（S100A6）。
